Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$119.56 USD

119.56
2,710,471

-0.72 (-0.60%)

Updated May 1, 2024 04:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

by Zacks Equity Research

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.

John Blank headshot

Where Might 2024 Investors Harvest Returns?

by John Blank

One source for those answers: Chief Investment Officers (CIOs).

Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee

by Zacks Equity Research

Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.

Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches

by Zacks Equity Research

Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

Why You Should Retain Walgreens Boots (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.

Here's Why Investors Should Retain Phibro (PAHC) for Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).

Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?

by Zacks Equity Research

Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Here's Why You Should Retain Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.

John Blank headshot

The FOMC, ECB, and BoJ: Global Week Ahead

by John Blank

Key risk market moments in the Global Week Ahead? They center on major central banks, with the U.S. Fed, the European Central Bank (ECB) and the Bank of Japan (BoJ) meeting.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

by Zacks Equity Research

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

by Zacks Equity Research

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.

Here's Why You Should Invest in IDEXX (IDXX) Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.

Zimmer (ZBH) Down 8.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.

Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)

by Zacks Equity Research

Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why You Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

ZBH vs. RMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ZBH vs. RMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.